Temelimab - GeNeuro
Alternative Names: GENHP-01; GNbAC-1; GNN-001Latest Information Update: 28 Jun 2024
At a glance
- Originator GeNeuro
- Class Anti-inflammatories; Antihyperglycaemics; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Multiple sclerosis; Post acute COVID 19 syndrome
- Suspended Type 1 diabetes mellitus
- No development reported Chronic inflammatory demyelinating polyradiculoneuropathy
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Chronic inflammatory demyelinating polyradiculoneuropathy in Unknown (IV, Infusion)
- 10 May 2024 GeNeuro completes a phase II trial for Post-acute-COVID-19-syndrome in Italy, Spain and Switzerland (IV) (NCT05497089) (EudraCT2022-000618-32)
- 16 Jan 2024 GeNeuro plans a phase III trial for Multiple sclerosis (IV) (GeNeuro pipeline, January 2024)